08:00 , Dec 2, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Topoisomerase I (TOP1) In vitro studies suggest that a class of TOP1 inhibitors could help treat cancer. Structure-based virtual screening...
08:00 , Jan 25, 2010 |  BC Week In Review  |  Clinical News

Tavocept: Phase III started

BioNumerik Pharmaceuticals Inc. , San Antonio, Texas   Product: Tavocept ( BNP7787 )   Business: Cancer   Molecular target: DNA   Description: Water soluble cisplatin   Indication: Treat advanced primary adenocarcinoma of the lung  ...
07:00 , Jul 21, 2008 |  BC Week In Review  |  Clinical News

Tavocept: Phase II data

In a U.S. Phase II trial in 151 patients with advanced NSCLC, Tavocept plus Taxotere docetaxel and cisplatin missed the co-primary endpoint of a significantly improved objective response rate vs. docetaxel plus cisplatin. The company...
07:00 , Apr 7, 2008 |  BioCentury  |  Finance

1Q approvals/1Q setbacks

1Q approvals/1Q setbacks 1Q approvals Selected first quarter product approvals. Company Approval Abbott (NYSE:ABT) FDA approves Simcor, a fixed-dose combination of extended-release niacin and immediate-release simvastatin, to manage cholesterol in patients with complex lipid disease...
07:00 , Mar 24, 2008 |  BC Week In Review  |  Clinical News

Tavocept: Phase III data

BioNumerik Pharmaceuticals Inc. , San Antonio, Texas   Product: Tavocept ( BNP7787 )   Business: Cancer   Molecular target: DNA   Description: Water soluble cisplatin   Indication: Prevent/reduce paclitaxel- and cisplatin-induced neurotoxicity in non-small cell...
00:51 , Mar 19, 2008 |  BC Extra  |  Clinical News

Tavocept misses Phase III endpoints

BioNumerik (San Antonio, Texas) said IV Tavocept ( BNP7787 ) did not meet the primary endpoint of preventing and reducing the severity of sporadic and cumulative neuropathy vs. placebo in a Japanese Phase III trial...
08:00 , Feb 11, 2008 |  BC Week In Review  |  Clinical News

Karenitecin: Phase III started

BioNumerik began an open-label, international Phase III trial in about 500 advanced ovarian cancer patients who are resistant to platinum- and taxane-based regimens to compare IV karenitecin vs. IV topotecan given daily for 5 consecutive...
07:00 , Aug 7, 2006 |  BC Week In Review  |  Clinical News

Tavocept: Phase III data

Data from a U.S. and European Phase III trial in about 750 breast cancer patients showed that Tavocept failed to reduce the incidence of chemotherapy-associated neuropathy vs. placebo, the primary endpoint. BioNumerik Pharmaceuticals Inc. ,...
07:00 , Aug 7, 2006 |  BC Week In Review  |  Clinical News

Tavocept: Phase III data

Data from a European Phase III trial in non-small cell lung cancer (NSCLC) patients showed that Tavocept missed the primary endpoint of increased tumor shrinkage rate vs. placebo. BioNumerik Pharmaceuticals Inc. , San Antonio, Texas...
07:00 , Jun 12, 2006 |  BioCentury  |  Finance

Ebb & Flow

Nobody disputes the notion that Elan's fortunes are more closely tied to multiple sclerosis drug Tysabri natalizumab than partner Biogen Idec's . Indeed, Tysabri news - be it good or bad - has typically led...